CSIMarket Company Name, Ticker, Suppliers, else..
 
Aquestive Therapeutics Inc   (NASDAQ: AQST)
 
Price: $5.1100 $0.09 1.793%
Day's High: $5.125 Week Perf: 0.59 %
Day's Low: $ 4.91 30 Day Perf: 38.29 %
Volume (M): 1,907,006 52 Wk High: $ 7.55
Volume (M$): $ 0 52 Wk Avg: $4.76
Open: $4.97 52 Wk Low: $2.93



 Market Capitalization (Millions $) 627
 Shares Outstanding (Millions) 123
 Employees 147
 Revenues (TTM) (Millions $) 50
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) 42
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aquestive Therapeutics Inc. is a pharmaceutical company that focuses on developing and commercializing innovative products to address unmet medical needs. The company specializes in oral drug delivery solutions, offering proprietary technology platforms that enable the development of orally administered therapeutics for a wide range of diseases and conditions. Aquestive Therapeutics aims to improve the treatment experience for patients by providing alternatives to injections or infusions. The company's portfolio includes products for central nervous system and neurology disorders, as well as treatments for rare diseases. Aquestive Therapeutics is dedicated to advancing drug delivery technology and transforming the way medications are administered.


   Company Address: 30 Technology Drive Warren 7059 NJ
   Company Phone Number: 941-1900   Stock Exchange / Ticker: NASDAQ AQST


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
PFE        1.75% 
• View Complete Report
   



Clinical Study

Aquestive Therapeutics Secures New Patents for Anaphylm Amid Revenue Challenges,

Published Wed, Oct 8 2025 12:04 PM UTC

Aquestive Therapeutics Expands Intellectual Property for Anaphylm Amidst Challenging Financial Landscape Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company known for pioneering advanced medication delivery technologies, has announced a significant expansion of its intellectual property portfolio. According to a recent press release dated October 8, 2025, t...
Management Announcement

Navigating Innovation and Financial Turbulence: Aquestive Therapeutics Aims for a Breakthrough in Allergy and Epilepsy Treatment

Published Wed, Feb 12 2025 12:00 PM UTC

In the fast-paced world of pharmaceuticals, where innovation often dances on the precipice of financial stability, Aquestive Therapeutics Inc. (NASDAQ: AQST) stands at a crossroads. As the company prepares to unveil new findings on its investigational drug, Anaphylm—an epinephrine sublingual film aimed at combating severe allergic reactions, including anaphylaxis—their n...
Management Announcement

Headlining Innovation Amid Losses: Aquestive Therapeutics Charts 2025 Course with Focus on Pediatric Epilepsy Solutions

Published Mon, Jan 13 2025 12:01 PM UTC

As 2025 unfolds, a spotlight shines on Aquestive Therapeutics Inc. (NASDAQ: AQST), a Warren, N.J.-based pharmaceutical company currently navigating both turbulent fiscal waters and vital advancements in pediatric neurology. The firm recently shared a multi-faceted business update underscoring its commitment to innovative drug delivery platforms and focused objectives. Howev...
Product Service News

U.S. FDA Grants Orphan Drug Exclusivity to Aquestive Therapeutics for Libervant (Diazepam) Buccal Film in Young Pedia...

Published Thu, Dec 19 2024 1:00 PM UTC

Factual In a significant advancement for pediatric neurology, Aquestive Therapeutics has announced that the United States Food and Drug Administration (U.S. FDA) has granted Orphan Drug Exclusivity for its product, Libervant (diazepam) Buccal Film. This approval specifically pertains to the treatment of seizure clusters in children aged two to five years.Orphan Drug Exclusi...
Product Service News

Unlocking New Possibilities: Aquestive Therapeutics Bolsters Pediatric Epilepsy Care and Advances Anaphylaxis Treatment

Published Mon, Apr 29 2024 11:00 AM UTC

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual FilmWARREN, N.J., April 29, 2024 - Aquestive Therapeutics, a leading pharmaceutical company focused on innovative science and delivery technologies, has made significant advancement...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.46
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.49
Working Capital Ratio 4.1
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.65 $
Revenues (TTM) 0.41 $
Cash Flow (TTM) 0.34 $
Cash 0.9 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 341,980
Net Income per Employee (TTM) -468,782
Receivable Turnover Ratio (TTM) 8.16
Inventory Turnover Ratio (TTM) 2.43
Asset Turnover Ratio (TTM) 0.36

Profitability Ratios Current
Gross Margin (MRQ) 75.99 %
Operating Margin (MRQ) -29.1 %
Net Margin (MRQ) -55.77 %
Net Cash Flow Margin (MRQ) -72.23 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Aquestive Therapeutics Inc's Segments
Reportable Segment    100 % of total Revenue
Manufacture and supply revenue    60.87 % of total Revenue
License and royalty revenue a    37.35 % of total Revenue
License and royalty revenue a Zevra And Commave Therapeutics Agreement    31.15 % of total Revenue
Co-development and research fees    1.79 % of total Revenue
United States    91.69 % of total Revenue
Ex-United States    8.31 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.